Addressing the context and consequences of substance use, misuse, and dependence: A global imperative

1. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012. doi: 10.1016/S2215-0366(18)30337-7 30392731

2. Harwood H, Fountain D, Livermore G. The economic costs of alcohol and drug abuse in the United States, 1992. Rockville: US National Institute on Drug Abuse; 1992.

3. Kendler KS. Levels of explanation in psychiatric and substance use disorders: implications for the development of an etiologically based nosology. Mol Psychiatry. 2012;17(1):11–21. doi: 10.1038/mp.2011.70 21670729

4. Tarter RE, Vanyukov MM. Introduction: theoretical and operational framework for research into the etiology of substance use disorders. J Child Adolesc Subst Abuse. 2001;10(4):1–12.

5. Tsai AC, Mendenhall E, Trostle JA, Kawachi I. Co-occurring epidemics, syndemics, and population health. Lancet. 2017;389(10072):978–28. doi: 10.1016/S0140-6736(17)30403-8 28271848

6. Singer M. A dose of drugs, a touch of violence, a case of AIDS: conceptualizing the SAVA syndemic. Free Inq Creative Sociol. 1996;24(2):99–110.

7. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief No. 328. Hyattsville: US National Center for Health Statistics, 2018.

8. Orpana HM, Lang JJ, George D, Halverson J. At-a-glance–The impact of poisoning-related mortality on life expectancy at birth in Canada, 2000 to 2016. Health Promot Chronic Dis Prev Can. 2019;39(2):56–60. doi: 10.24095/hpcdp.39.2.03 30767855

9. Guttmann A, Blackburn R, Amartey A, Zhou L, Wijlaars L, Saunders N, et al. Long-term mortality in mothers of infants with neonatal abstinence syndrome: A population-based parallel-cohort study in England and Ontario, Canada. PLoS Med. 2019;16(11):e1002974. doi: 10.1371/journal.pmed.1002974

10. MacLeod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, et al. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019;16(11):e1002965. doi: 10.1371/journal.pmed.1002965

11. Ding KY, Mosdol A, Hov L, Staumann GH, Vist GE. The effects of concurrent prescription of benzodiazepines for people undergoing opioid maintenance treatment: systematic review. Report from the Norwegian Institute of Public Health No. 2016–27. Oslo: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health; 2016.

12. Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment–A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64. doi: 10.1016/j.drugalcdep.2017.01.013 28315808

13. US Food and Drug Administration. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Rockville: US Food and Drug Administration; 2017.

14. Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief No. 329. Hyattsville: US National Center for Health Statistics; 2018.

15. Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to Its social and economic determinants. Am J Public Health. 2018;108(2):182–6. doi: 10.2105/AJPH.2017.304187 29267060

16. Ruhm CJ. Drivers of the fatal drug epidemic. J Health Econ. 2019;64:25–42. doi: 10.1016/j.jhealeco.2019.01.001 30784811

17. King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990–2013: a systematic review. Am J Public Health. 2014;104:e32–e42. doi: 10.2105/AJPH.2014.301966 24922138

18. Venkataramani AS, Bair EF, O'Brien RL, Tsai AC. A difference-in-differences analysis of the association between automotive assembly plant closures and opioid overdose mortality in the United States. JAMA Intern Med 2020;180(2):1–9. doi: 10.1001/jamainternmed.2019.5686

19. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44. doi: 10.1016/j.socscimed.2004.12.024 15955404

20. Li ZR, Xie E, Crawford FW, Warren JL, McConnell K, Copple JT, et al. Suspected heroin-related overdose incidents in Cincinnati, Ohio: A spatiotemporal analysis. PLoS Med. 2019;16(11):e1002956. doi: 10.1371/journal.pmed.1002956

21. Wei Y-JJ, Chen C, Fillingim R, Schmidt SO, Winterstein AG. Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006–2016: A cross-sectional study. PLoS Med. 2019;16(11):e1002941. doi: 10.1371/journal.pmed.1002941

22. Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study. PLoS Med. 2019;16(11):e1002922. doi: 10.1371/journal.pmed.1002922

23. Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerdá M, et al. Prescription opioid use disorder and heroin use among 12–34 year-olds in the United States from 2002 to 2014. Addict Behav. 2017;65:236–41. doi: 10.1016/j.addbeh.2016.08.033 27614657

24. Monnat SM, Rigg KK. Examining rural/urban differences in prescription opioid misuse among US adolescents. J Rural Health. 2016;32(2):204–18. doi: 10.1111/jrh.12141 26344571

25. Edlund MJ, Forman-Hoffman VL, Winder CR, Heller DC, Kroutil LA, Lipari RN, et al. Opioid abuse and depression in adolescents: Results from the National Survey on Drug Use and Health. Drug Alcohol Depend. 2015;152:131–8. doi: 10.1016/j.drugalcdep.2015.04.010 25981310

26. Schepis TS, Krishnan-Sarin S. Characterizing adolescent prescription misusers: a population-based study. J Am Acad Child Adolesc Psychiatry. 2008;47(7):745–54. doi: 10.1097/CHI.0b013e318172ef0ld 18520963

27. Ballantyne JC, Sullivan MD. Intensity of chronic pain—the wrong metric? N Engl J Med. 2015;373(22):2098–9. doi: 10.1056/NEJMp1507136 26605926

28. Baker DW. History of The Joint Commission’s pain standards: lessons for today’s prescription opioid epidemic. JAMA. 2017;317(11):1117–8. doi: 10.1001/jama.2017.0935 28241189

29. Sharfstein JM, Olsen Y. Making amends for the opioid epidemic. JAMA. 2019;321(15):1446–7. doi: 10.1001/jama.2019.3505 30990541

30. Todd KH, Deaton C, D'Adamo AP, Goe L. Ethnicity and analgesic practice. Ann Emerg Med. 2000;35(1):11–6. doi: 10.1016/s0196-0644(00)70099-0 10613935

31. Ng B, Dimsdale JE, Rollnik JD, Shapiro H. The effect of ethnicity on prescriptions for patient-controlled analgesia for post-operative pain. Pain. 1996;66(1):9–12. doi: 10.1016/0304-3959(96)02955-7 8857626

32. Bernabei R, Gambassi G, Lapane K, Landi F, Gatsonis C, Dunlop R, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA. 1998;279(23):1877–82. doi: 10.1001/jama.279.23.1877 9634258

33. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi: 10.1136/bmj.j1550 28446428

34. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–45. doi: 10.7326/M17-3107 29913516

35. Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions and outcomes among correctional populations: a systematic review. PLoS Med. Forthcoming 2019

36. Robertson AM, Garfein RS, Wagner KD, Mehta SR, Magis-Rodriguez C, Cuevas-Mota J, et al. Evaluating the impact of Mexico's drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA, United States: a binational mixed methods research agenda. Harm Reduct J. 2014;11:4. doi: 10.1186/1477-7517-11-4 24520885

37. Cheng T, Small W, Nosova E, Hogg B, Hayashi K, Kerr T, et al. Nonmedical prescription opioid use and illegal drug use: initiation trajectory and related risks among people who use illegal drugs in Vancouver, Canada. BMC Res Notes. 2018;11(1):35. doi: 10.1186/s13104-018-3152-9 29338770

38. Morris MD, Brouwer KC, Lozada RM, Gallardo M, Vera A Strathdee SA. “Injection first”: a unique group of injection drug users in Tijuana, Mexico. Am J Addict. 2012;21(1):23–30. doi: 10.1111/j.1521-0391.2011.00194.x 22211343

39. Marks C, Borquez A, Jain S, Sun X, Strathdee SA, Garfein RS, et al. Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLoS Med. 2019;16(11):e1002973. doi: 10.1371/journal.pmed.1002973

40. US Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville: Center for Behavioral Health Statistics and Quality, U.S. Substance Abuse and Mental Health Services Administration; 2019.

41. Yedinak JL, Goedel WC, Paull K, Lebeau R, Krieger M, Thompson C, et al. Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. PLoS Med. 2019;16(11):e1002963. doi: 10.1371/journal.pmed.1002963

42. Eisenberg JM, Power EJ. Transforming insurance coverage into quality health care: voltage drops from potential to delivered quality. JAMA. 2000;284(16):2100–7. doi: 10.1001/jama.284.16.2100 11042759

43. Giordano TP, Suarez-Almazor ME, Grimes RM. The population effectiveness of highly active antiretroviral therapy: are good drugs good enough? Curr HIV/AIDS Rep. 2005;2(4):177–83. doi: 10.1007/s11904-005-0013-7 16343375

44. Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, Degroot A, et al. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS. 2005;19(12):1309–15. doi: 10.1097/01.aids.0000180102.88511.7d 16052086

45. Pence BW, O'Donnell JK, Gaynes BN. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012;26(5):656–8. doi: 10.1097/QAD.0b013e3283519aae 22398574

46. Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a Cascade of Care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1–10. doi: 10.1080/00952990.2018.1546862 30675818

47. Lake S, Walsh Z, Kerr T, Cooper ZD, Buxton J, Wood E, et al. Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis. PLoS Med. 2019;16(11):e1002967. doi: 10.1371/journal.pmed.1002967

48. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Int Med. 2014;174(10):1668–73. doi: 10.1001/jamainternmed.2014.4005 25154332

49. Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J Health Econ. 2018;58:29–42. doi: 10.1016/j.jhealeco.2017.12.007 29408153

50. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37. doi: 10.1016/S0140-6736(10)62353-7 21497898

51. Caulkins JP, Pardo B, Kilmer B. Supervised consumption sites: a nuanced assessment of the causal evidence. Addiction. Epub 2019 Jul 16. doi: 10.1111/add.14747 31309637

52. Kennedy MC, Hayashi K, Milloy M-J, Wood E, Kerr T. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. PLoS Med. 2019;16(11):e1002964. doi: 10.1371/journal.pmed.1002964

53. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078–83. doi: 10.1073/pnas.1518393112 26575631

54. Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018;108(10):1394–400. doi: 10.2105/AJPH.2018.304590 30138057

55. Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, et al. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open. 2019;2(2):e187621. doi: 10.1001/jamanetworkopen.2018.7621 30707224

56. Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969. doi: 10.1371/journal.pmed.1002969

57. McKetta S, Keyes KM. Heavy and binge alcohol drinking and parenting status in the United States from 2006 to 2018: An analysis of nationally representative cross-sectional surveys. PLoS Med. 2019;16(11):e1002954. doi: 10.1371/journal.pmed.1002954

58. Besbris M, Faber JW, Rich P, Sharkey P. Effect of neighborhood stigma on economic transactions. Proc Natl Acad Sci U S A. 2015;112(16):4994–8. doi: 10.1073/pnas.1414139112 25848041

59. Hasin DS, Shmulewitz D, Keyes K. Alcohol use and binge drinking among U.S. men, pregnant and non-pregnant women ages 18–44: 2002–2017. Drug Alcohol Depend. 2019;205:107590. doi: 10.1016/j.drugalcdep.2019.107590 31600616

60. Harris S, Dykxhoorn J, Hollander A-C, Dalman C, Kirkbride JB. Substance use disorders in refugee and migrant groups in Sweden: A nationwide cohort study of 1.2 million people. PLoS Med. 2019;16(11):e1002944. doi: 10.1371/journal.pmed.1002944

61. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–74. doi: 10.7326/M16-2607 28693043

62. Fatseas M, Serre F, Alexandre JM, Debrabant R, Auriacombe M, Swendsen J. Craving and substance use among patients with alcohol, tobacco, cannabis or heroin addiction: a comparison of substance- and person-specific cues. Addiction. 2015;110(6):1035–42. doi: 10.1111/add.12882 25688760

63. Humphreys K, Blodgett JC, Wagner TH. Estimating the efficacy of Alcoholics Anonymous without self-selection bias: an instrumental variables re-analysis of randomized clinical trials. Alcohol Clin Exp Res. 2014;38(11):2688–94. doi: 10.1111/acer.12557 25421504

64. Cerdá M, Diez-Roux AV, Tchetgen ET, Gordon-Larsen P, Kiefe C. The relationship between neighborhood poverty and alcohol use: estimation by marginal structural models. Epidemiology. 2010;21(4):482–9. doi: 10.1097/EDE.0b013e3181e13539 20498603

65. Carpenter C, Dobkin C. The effect of alcohol consumption on mortality: regression discontinuity evidence from the minimum drinking age. Am Econ J Appl Econ. 2009;1(1):164–82. doi: 10.1257/app.1.1.164 20351794

66. Maclean JC, Saloner B. Substance use treatment provider behavior and healthcare reform: evidence from Massachusetts. Health Econ. 2018;27(1):76–101. doi: 10.1002/hec.3484 28224675

67. Hansen H, Lopez-Iftikhar MM, Alegria M. The economy of risk and respect: accounts by Puerto Rican sex workers of HIV risk taking. J Sex Res. 2002;39(4):292–301. doi: 10.1080/00224490209552153 12545412

68. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8(2):171–83. doi: 10.1111/j.1526-4637.2006.00255.x 17305688

69. Ritter A. Studying illicit drug markets: Disciplinary contributions. Int J Drug Policy. 2006;17(6):453–63